ABSTRACT

The aim of the study was to determine the potential influence of Allicin on pharmacokinetics and pharmacodynamics of Glimepiride in alloxan induced diabetic rats. In this study, alloxan monohydrate (120mg/kg) was used to induce diabetes in rats. These rats were divided into 5 groups (n=6)). Group 1 was considered as control, group 2 treated with Glimepiride, group3 with Allicin, group 4 and 5were pretreated with Allicin for single day and for eight days respectively, by the end of the Allicin pretreatment Glimepiride was given. Blood samples were collected by retro orbital plexusat different time intervals and pharmacokinetic and pharmacodynamic parameters were measured. The total antioxidant status was also estimated by sub acute treatment of above groups. Allicin significantly increased the area under the curve (AUC) of glimepiride in both single and multiple dose study, Cmax, AUCtot and MRT were also increased. In pharmacodynamic study, the glucose levels were significantly reduced upon pre treatment with Allicin.The total antioxidant status was gradually more increased in Allicin - Glimepiride treated group when compared with Allicin, Glimepiride alone treated (group 2 and 3) and control groups. The results in present study revealed that combination of Glimepiride with Allicin enhances the bioavailability and hypoglycemic effect of Glimepiride due to inhibition of CYP2C9 enzyme which suggested that Allicin might be beneficial as an adjuvant for the treatment of diabetes with Glimepiride in a proper dose. Keywords: CYP2C9, Allicin, Glimepiride, Pharmacokinetic, Pharmacodynamic, enzyme inhibition
Publication date: 01/11/2020

https://ijbpas.com/pdf/2020/November/MS_IJBPAS_2020_5260.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2020/9.11.5260